WOODCLIFF LAKE

Bannix and GBT Partner to Bring Revolutionary Imaging Tech "VisionWave" to Market

Retrieved on: 
Thursday, March 28, 2024

VisionWave has promise to revolutionize imaging and detection, particularly in military/combat and geological survey applications.

Key Points: 
  • VisionWave has promise to revolutionize imaging and detection, particularly in military/combat and geological survey applications.
  • While the path to commercialization requires additional research, development, and strategic partnerships for successful market introduction, both Bannix and VisionWave are confident in the transformative potential of VisionWave.
  • This innovative technology has the potential to redefine imaging and detection across various industries, from military applications to security and medical diagnostics.
  • There is no guarantee that Bannix or Tokenize will overcome these hurdles.

CloudCasa by Catalogic Simplifies Kubernetes Migration and Replication, Deepens Support for Microsoft Azure Kubernetes Service

Retrieved on: 
Tuesday, March 19, 2024

Customers of Azure Kubernetes Service (AKS) can now use the new migration workflow to easily migrate AKS worker nodes to Azure Linux , migrate storage volumes from Azure Disk to Azure Container Storage , and migrate from other cloud managed Kubernetes services and from on-premises Kubernetes environments to AKS.

Key Points: 
  • Customers of Azure Kubernetes Service (AKS) can now use the new migration workflow to easily migrate AKS worker nodes to Azure Linux , migrate storage volumes from Azure Disk to Azure Container Storage , and migrate from other cloud managed Kubernetes services and from on-premises Kubernetes environments to AKS.
  • CloudCasa protects Kubernetes environments and provides a cyber-resilient and cloud-integrated backup, disaster recovery and migration solution for cloud native applications.
  • CloudCasa is the first “born in the cloud” backup service built with Kubernetes for Kubernetes environments.
  • “We are excited to introduce CloudCasa support for Kubernetes migration and replication workflows as new use cases for backup and recovery.

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Retrieved on: 
Monday, March 18, 2024

WEST HOLLYWOOD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from March 14, 2024 for an additional month, to April 14, 2024.

Key Points: 
  • WEST HOLLYWOOD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from March 14, 2024 for an additional month, to April 14, 2024.
  • As previously disclosed, at an annual meeting of its stockholders held on March 8, 2024, Bannix’ stockholders voted in favor of a proposal to amend Bannix’s Amended and Restated Certificate of Incorporation (as amended, the “Amended Charter”) to provide Bannix with the right to extend the Deadline Date up to six times for an additional one month each time (the “Extension”) until September 14, 2024.
  • Also as previously announced, if an Extension is implemented, the sponsor of Bannix, Instant Fame LLC (the “Sponsor”), or its designees will deposit into the trust account, as a loan, the lesser of (x) $25,000 and (y) $0.05 for each share that is not redeemed in connection with the annual meeting.
  • On March 14, 2024, the Board, at the request of the Sponsor, decided to implement the thirteen Extension and to extend the Deadline Date for an additional month to April 14, 2024.

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Retrieved on: 
Tuesday, February 20, 2024

WEST HOLLYWOOD, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from February 14, 2024 for an additional month, to March 14, 2024.

Key Points: 
  • WEST HOLLYWOOD, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from February 14, 2024 for an additional month, to March 14, 2024.
  • On March 9, 2023, Bannix filed the Amended Charter with the Secretary of State of the State of Delaware.
  • Also as previously announced, if an Extension is implemented, the sponsor of Bannix, Instant Fame LLC (the “Sponsor”), or its designees will deposit into the trust account, as a loan, the lesser of (x) $75,000 and (y) $0.07 for each share that is not redeemed in connection with the special meeting.
  • On February 15, 2024, the Board, at the request of the Sponsor, decided to implement the twelfth Extension and to extend the Deadline Date for an additional month to March 14, 2024.

CloudCasa by Catalogic Executes Strategic Growth Initiatives and Garners Analyst Accolades

Retrieved on: 
Wednesday, January 24, 2024

CloudCasa protects Kubernetes environments and provides a cyber-resilient, hybrid and cloud integrated backup, disaster recovery and migration solution for cloud native applications.

Key Points: 
  • CloudCasa protects Kubernetes environments and provides a cyber-resilient, hybrid and cloud integrated backup, disaster recovery and migration solution for cloud native applications.
  • CloudCasa is the first “born in the cloud” backup service built with Kubernetes for Kubernetes environments.
  • CloudCasa addresses management, governance, and compliance requirements for OpenShift environments by combining the benefits of open source and SaaS management.
  • We’ve seen continued adoption, accelerated by our joining the Azure Marketplace,” said Sathya Sankaran, General Manager of CloudCasa by Catalogic.

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Retrieved on: 
Thursday, January 18, 2024

WEST HOLLYWOOD, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from January 14, 2024 for an additional month, to February 14, 2024.

Key Points: 
  • WEST HOLLYWOOD, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from January 14, 2024 for an additional month, to February 14, 2024.
  • As previously disclosed, at a special meeting of its stockholders held on March 8, 2023, Bannix’ stockholders voted in favor of a proposal to amend Bannix’s Amended and Restated Certificate of Incorporation (as amended, the “Amended Charter”) to provide Bannix with the right to extend the Deadline Date up to 12 times for an additional one month each time (the “Extension”) until March 14, 2024.
  • On March 9, 2023, Bannix filed the Amended Charter with the Secretary of State of the State of Delaware.
  • On January 14, 2024, the Board, at the request of the Sponsor, decided to implement the eleven Extension and to extend the Deadline Date for an additional month to February 14, 2024.

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

Retrieved on: 
Thursday, January 18, 2024

WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio.

Key Points: 
  • WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio.
  • Eagle is also announcing that the U.S. Patent and Trademark Office has granted U.S. Patent Nos.
  • 11844783 (the “‘783 patent”) and 11872214 (the “‘214 patent”) covering Eagle’s innovative bendamustine liquid formulations.
  • Eagle cannot predict the timing or ultimate outcome of the litigation described above or the impact of this litigation on its business.

PKF O'Connor Davies Announces 2024 Partner Promotions

Retrieved on: 
Tuesday, January 16, 2024

NEW YORK, Jan. 16, 2024 /PRNewswire-PRWeb/ -- PKF O'Connor Davies, one of the nation's largest accounting, tax and advisory practices, today announced the promotion of 19 employees to leadership positions within the organization. Sumeet Agarwal, Jesse Allen, Darren Bushey, Benjamin Garcia, Christina Gray, Sarah Guilmette, Thomas Kelly, Michael Kettell, Jon Klerowski, Michael Koenecke, Jaron Lariviere, Roman Matatov, Ravi Melwani, Melissa Modelson, Joseph Parmegiani, Jackie Reinhard, Nicholas Rochedieu, Patrick Trask and Ioanna Vavasis have been elevated to the role of Partner.

Key Points: 
  • "Our 2024 Partner Class is comprised of high-performing, committed leaders who drive our organization forward and strengthen our reputation for excellence in countless ways," said Kevin J. Keane, Executive Chairman at PKF O'Connor Davies.
  • "Our 2024 Partner Class is comprised of high-performing, committed leaders who drive our organization forward and strengthen our reputation for excellence in countless ways," said Kevin J. Keane, Executive Chairman at PKF O'Connor Davies.
  • Christina Gray has built her professional career at PKF O'Connor Davies, starting with the organization over a decade ago as an intern.
  • PKF O'Connor Davies continues to expand through organic growth and acquisitions on the East Coast and beyond.

Bannix Acquisition Corp. Announces Monthly Extension to Complete its Initial Business Combination

Retrieved on: 
Thursday, December 14, 2023

WEST HOLLYWOOD, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from December 14, 2023 for an additional month, to January 14, 2024.

Key Points: 
  • WEST HOLLYWOOD, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Bannix Acquisition Corp. (“Bannix”) announced today that its board of directors (the “Board”) has decided to extend the date by which Bannix must consummate an initial business combination (the “Deadline Date”) from December 14, 2023 for an additional month, to January 14, 2024.
  • As previously disclosed, at a special meeting of its stockholders held on March 8, 2023, Bannix’ stockholders voted in favor of a proposal to amend Bannix’s Amended and Restated Certificate of Incorporation (as amended, the “Amended Charter”) to provide Bannix with the right to extend the Deadline Date up to 12 times for an additional one month each time (the “Extension”) until March 14, 2024.
  • On March 9, 2023, Bannix filed the Amended Charter with the Secretary of State of the State of Delaware.
  • On December 14, 2023, the Board, at the request of the Sponsor, decided to implement the ten Extension and to extend the Deadline Date for an additional month to January 14, 2024.

EGRX Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)

Retrieved on: 
Thursday, December 7, 2023

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”).

Key Points: 
  • NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”).
  • If you purchased Eagle securities and would like to discuss our investigation, your rights, or your interests please click here .
  • WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
  • For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .